A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

NCT02541383 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1085

Enrollment

NETWORK

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
DRUG: Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab
DRUG: Daratumumab

Sponsor

Intergroupe Francophone du Myelome

Collaborators

[object Object]
[object Object]